Cargando…

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massa, Horace, Nagar, Anindyt M., Vergados, Athanasios, Dadoukis, Panagiotis, Patra, Sudeshna, Panos, Georgios D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384476/ https://www.ncbi.nlm.nih.gov/pubmed/30556449 http://dx.doi.org/10.1177/0300060518816884

Ejemplares similares

Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatment of Refractory Cystoid Macular Oedema After Retinal Detachment Repair
por: Alfaqawi, Fadi, et al.
Publicado: (2018)

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
por: Mushtaq, Yusuf, et al.
Publicado: (2023)

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
por: Young, James F., et al.
Publicado: (2019)

Electronic Patient Records to Identify Patients in the United Kingdom with Diabetic Macular Oedema Suitable for ILUVIEN(®) (Fluocinolone Acetonide)
por: Butt, Farhat, et al.
Publicado: (2016)

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Correction to: Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2020)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
por: Pochopien, Michal, et al.
Publicado: (2019)

Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule
por: Alzaabi, Manal, et al.
Publicado: (2020)

Clinical utility of intravitreal fluocinolone acetonide (Iluvien(®)) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
por: Saedon, Habiba, et al.
Publicado: (2017)

Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants
por: Yang, Y, et al.
Publicado: (2015)

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
por: Messenger, Wyatt B, et al.
Publicado: (2013)

Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom
por: Bailey, C, et al.
Publicado: (2017)

Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study
por: Khoramnia, Ramin, et al.
Publicado: (2023)

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy
por: Lima-Fontes, Mário, et al.
Publicado: (2022)

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

A Novel Technique for Repositioning of a Migrated ILUVIEN(®) (Fluocinolone Acetonide) Implant into the Anterior Chamber
por: El-Ghrably, Ibraheem A., et al.
Publicado: (2015)

Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®)
por: Coelho, João, et al.
Publicado: (2019)

Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN(®) clinical evidence study in Portugal
por: Carneiro, Angela, et al.
Publicado: (2020)

Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy
por: Meireles, A, et al.
Publicado: (2017)

Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study
por: Ch’ng, Soon W., et al.
Publicado: (2017)

Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results
por: Dobler, Emilie, et al.
Publicado: (2022)

A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series
por: Schmit-Eilenberger, Vera K
Publicado: (2015)

Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema
por: Byun, Matthew, et al.
Publicado: (2020)

Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
por: Baillif, Stéphanie, et al.
Publicado: (2022)

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN(®))
por: Pessoa, Bernardete, et al.
Publicado: (2020)

Visual function and retinal morphological changes after single suprachoroidal delivery of fluocinolone acetonide (Iluvien®) implant in eyes with chronic diabetic macular edema
por: El Rayes, Ehab N., et al.
Publicado: (2023)

Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months
por: Moll-Udina, Aina, et al.
Publicado: (2023)

Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN(®))
por: Bodaghi, Bahram, et al.
Publicado: (2020)

Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series
por: Ahmed, Muna, et al.
Publicado: (2020)

Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN(®)) and Follow-Up Considerations/Recommendations
por: Adán, Alfredo, et al.
Publicado: (2020)

Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom
por: Alfaqawi, F, et al.
Publicado: (2017)

Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
por: Mansour, Sam E, et al.
Publicado: (2021)

Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges
por: Massa, Horace, et al.
Publicado: (2019)

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant
por: Bertelmann, Thomas, et al.
Publicado: (2015)

Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis
por: Park, Jong G., et al.
Publicado: (2020)

Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study
por: Rousseau, Nicolas, et al.
Publicado: (2023)

Bilateral 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the Successful Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Secondary Macular Oedema: A Case Report and Review of Intravitreal Therapies
por: Ansari, Abdus Samad, et al.
Publicado: (2021)

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p2jgbuu73ue0mjqj8b2mu03atf